← Back to Search

Chemotherapy

Combination Chemotherapy for Lung Cancer

Phase 2

Waitlist Available

Research Sponsored by Raghu Nandan, M.D., Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Creatinine no greater than 1.5 mg/dL AND/OR Creatinine clearance at least 60 mL/min

No uncontrolled arrhythmia

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well combination chemotherapy works in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Who is the study for?

This trial is for adults over 18 with advanced non-small cell lung cancer (stage IIIB or IV). Participants must not be pregnant, should use contraception if fertile, and cannot have HIV. They need normal organ function tests and no recent heart attacks. Those with brain metastases or prior chemotherapy are excluded.Check my eligibility

What is being tested?

The study is testing the effectiveness of combining different chemotherapy drugs to treat patients with advanced non-small cell lung cancer. It's a Phase II trial, which means it's looking at how well these drug combinations work and their safety.See study design

What are the potential side effects?

Chemotherapy can cause side effects like nausea, vomiting, hair loss, fatigue, increased risk of infection due to low blood counts, mouth sores, and potential damage to organs such as the liver or kidneys.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney function is normal, with creatinine levels at or below 1.5 mg/dL or clearance above 60 mL/min.

Select...

My heart rhythm is stable and controlled.

Select...

I do not have congestive heart failure.

Select...

My lung cancer is at an advanced stage (IIIB or IV).

Select...

My cancer can be measured by medical tests.

Select...

I am over 18 years old.

Select...

I can take care of myself and am up and about more than 50% of my waking hours.

Select...

I haven't had any cancer in the past 5 years, except for skin cancer.

Select...

It's been over 4 weeks since my last radiotherapy and my cancer has gotten worse.

Select...

I have not had a heart attack in the last 6 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 10Eligibility criteria met

Find a Location

Who is running the clinical trial?

Raghu Nandan, M.D., IncLead Sponsor

1 Previous Clinical Trials

39 Total Patients Enrolled

Raghu Nandan, MDStudy ChairRaghu Nandan, M.D., Inc

1 Previous Clinical Trials

39 Total Patients Enrolled

Media Library

Combination Chemotherapy (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT00005825 — Phase 2

Lung Cancer Clinical Trial 2023: Combination Chemotherapy Highlights & Side Effects. Trial Name: NCT00005825 — Phase 2

Combination Chemotherapy (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00005825 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are opportunities still available to join this experiment?

"Unfortunately, the information hosted on clinicaltrials.gov indicates that this particular medical trial is no longer accepting participants; despite having been initially posted in September 1998 and last updated in December 2013. However, there are presently 2041 other studies actively recruiting patients."

Answered by AI

Has this course of therapy been ratified by the FDA?

"Given the Phase 2 status of this treatment, there is sufficient evidence to suggest its safety and thus our team at Power have assigned it a score of 2. Nonetheless, data supporting efficacy has yet to be established."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

1998. "Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00005825.

All > Lung > Sclc